Neurologist Karl Kieburtz, M.D., M.P.H. will be taking over the roles of director of the Clinical and Translational Science Institute (CTSI) and senior associate dean for Clinical Research at the beginning of September. He will replace Thomas Pearson, M.D., M.P.H., Ph.D. who is taking a position at the University of Florida.
Kieburtz is a nationally-recognized expert in the design and operation of clinical trials and has helped establish networks of investigators that serve as the hub for many of the world’s largest studies of new treatments for neurological conditions. Kieburtz is currently the director of the Center for Experimental Therapeutics (CHET), a position he will retain. CHET is a unique academic-based center that full offers a full array of services and scientific expertise essential to the conduct of early, learning phase clinical trials for industry, foundations, and government sponsors.
The URMC CTSI provides researchers with a comprehensive and integrated set of services, expertise, and resources necessary to carry out all phases of translational research from the point where a new idea is first evaluated in people all the way to its adoption on a community-wide scale to improve health.
Read more about Kieburtz appointment here.
Mark Michaud |
| 0 comments